Richard H. Scheller Ph.D.
Net Worth

Last updated:

What is Richard H. Scheller Ph.D. net worth?

The estimated net worth of Dr. Richard H. Scheller Ph.D. is at least $19,079,478 as of 16 Feb 2023. He owns shares worth $2,281,535 as insider, has earned $12,897,943 from insider trading and has received compensation worth at least $3,900,000 in BridgeBio Pharma, Inc..

What is the salary of Richard H. Scheller Ph.D.?

Dr. Richard H. Scheller Ph.D. salary is $650,000 per year as Chairman of R&D and Director in BridgeBio Pharma, Inc..

How old is Richard H. Scheller Ph.D.?

Dr. Richard H. Scheller Ph.D. is 72 years old, born in 1953.

What stocks does Richard H. Scheller Ph.D. currently own?

As insider, Dr. Richard H. Scheller Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
BridgeBio Pharma, Inc. (BBIO) Chairman of R&D and Director 45,860 $49.75 $2,281,535

What does BridgeBio Pharma, Inc. do?

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BBIO logo
BBIO
BridgeBio Pharma, Inc.
$49.75

Richard H. Scheller Ph.D. insider trading

BridgeBio Pharma, Inc.

Dr. Richard H. Scheller Ph.D. has made 7 insider trades between 2019-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 163,427 units of BBIO stock on 1 Jul 2019. As of 16 Feb 2023 he still owns at least 45,860 units of BBIO stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Units 3,196 N/A N/A
Option
Common Stock 3,196 N/A N/A
Option
Restricted Stock Units 3,196 N/A N/A
Option
Common Stock 3,196 N/A N/A
Option
Common Stock 3,196 N/A N/A
Option
Restricted Stock Units 3,196 N/A N/A
Option
Common Stock 3,195 N/A N/A
Option
Restricted Stock Units 3,195 N/A N/A
Option
Common Stock 13,777 $17 $234,209
Option
Stock Option (Right to Buy) 13,777 $17 $234,209
Sale
Common Stock 13,777 $17 $234,209
Sale
Common Stock 60,401 $65.15 $3,934,823
Sale
Common Stock 60,401 $65.15 $3,934,823
Sale
Common Stock 30,000 N/A N/A
Sale
Common Stock 30,000 $65.39 $1,961,550
Option
Stock Option (Right to Buy) 29,277 $17 $497,709
Sale
Common Stock 31,443 $60.27 $1,895,038
Option
Common Stock 29,277 $17 $497,709
Sale
Common Stock 25,000 $37.5 $937,500
Option
Common Stock 163,427 N/A N/A
Option
Common Units 6,886 N/A N/A

BridgeBio Pharma key executives

BridgeBio Pharma, Inc. executives and other stock owners filed with the SEC: